Anti-HIV activity of new higher order G-quadruplex aptamers obtained from tetra-end-linked oligonucleotides
By combining the ability of short G-rich oligodeoxyribonucleotides (ODNs) containing the sequence 5 ′CGGA 3 ′ to form higher order G-quadruplex (G4) complexes with the tetra-end-linked (TEL) concept to produce aptamers targeting the HIV envelope glycoprotein 120 (gp120), three new TEL-ODNs ( 1-3 ) h...
Gespeichert in:
Veröffentlicht in: | Organic & biomolecular chemistry 2018-03, Vol.16 (13), p.2349-2355 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | By combining the ability of short G-rich oligodeoxyribonucleotides (ODNs) containing the sequence
5
′CGGA
3
′ to form higher order G-quadruplex (G4) complexes with the tetra-end-linked (TEL) concept to produce aptamers targeting the HIV envelope glycoprotein 120 (gp120), three new TEL-ODNs (
1-3
) having the sequence
5
′CGGAGG
3
′ were synthesized with the aim of studying the effect of G4 dimerization on their anti-HIV activity. Furthermore, in order to investigate the effect of the groups at the 5′ position, the 5′ ends of
1-3
were left uncapped (
1
) or capped with either the lipophilic dimethoxytrityl (DMT) (
2
) or the hydrophilic glucosyl-4-phosphate (
3
) moieties. The here reported results demonstrate that only the DMT-substituted TEL-ODN
2
is effective in protecting human MT-4 cell cultures from HIV infection (76% max protection), notwithstanding all the three new aptamers proved to be capable of forming stable higher order dimeric G4s when annealed in K
+
-containing buffer, thus suggesting that the recognition of a hydrophobic pocket on the target glycoprotein by the aptamers represents a main structural feature for triggering their anti-HIV activity.
The synthesis of a new dimeric G-quadruplex-based DNA aptamer endowed with anti-HIV activity is reported. |
---|---|
ISSN: | 1477-0520 1477-0539 |
DOI: | 10.1039/c7ob02346d |